DOCSLIB.ORG

Underground Steroid Handbook Ii

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Underground Steroid Handbook Ii Copyright © 1989 by Daniel Duchaine Copyright © 2006 by QFAC, Inc. All Rights Reserved. UNDERGROUND STEROID HANDBOOK II Incorporating material from the original Underground Steroid Handbook, Ultimate Muscle Mass, and the USH Updates #1-10 by DANIEL DUCHAINE HLR technical books, venice, ca 90291 Copyright © 1989 by Daniel Duchaine Copyright © 2006 by QFAC, Inc. All Rights Reserved. REVISED EDITION FIRST PRINTING Printed in the United States of America Reproduction or publication of the content in any manner, without express permission of the author or publisher, is prohibted. No liability is assumed with respect to the use of the information herein. Copyright © 1989 by Daniel Duchaine Copyright © 2006 by QFAC, Inc. Cover art by Tara Lee Torburn Photograph courtesty of Modern Bodybuilding Publications Copyright © 1989 by Daniel Duchaine Copyright © 2006 by QFAC, Inc. All Rights Reserved. Contents 1 PREFACE TO THE SECOND EDITION 2 WHY THIS BOOK HAD TO BE WRITTEN AGAIN 3 BEFORE YOUR READ ANY MORE OF THIS BOOK 4 ABOUT STEROIDS IN GENERAL 5 THE VARIOUS KINDS OF STEROIDS 6 ABOUT BLOOD TESTS 7 THE DRUGS IN PARTICULAR 8 USING THE DRUGS 9 STEROID SIDE EFFECTS 10 NEEDLE ARCANA 11 HUMAN GROWTH HORMONE 12 GETTING OFF STEROIDS 13 THE DRUG TEST 14 YOU, STEROIDS, AND THE LAW Copyright © 1989 by Daniel Duchaine Copyright © 2006 by QFAC, Inc. All Rights Reserved. CHAPTER ONE PREFACE TO THE SECOND EDITION Honesty, I never, never thought about doing a second edition to the UNDERGROUND STEROID HANDBOOK. There should be many more interesting, socially acceptable things for me to do, and life is so short, even if I didn't use steroids. If you never heard about or read the first edition of the UNDERGROUND STEROID HANDBOOK let me give you a little background. I wrote the original Underground Steroid Handbook (USH) early in 1982. It was essentially a 'how to' course on steroids, written over a two week period under the influence of a megadose of Testosterone Cypionate. Let me be the first to tell you about the recent hormone research: a high testosterone level does not impair your verbal skills, it just makes them seemingly unintelligible (read: warped and sick) to people with high estrogen levels. The USH crammed 18 pages with tiny, almost impossible to read type and tried to touch all the bases about the real world use of anabolic/androgenic steroids as I know it then, in 1982. The pamphlet was easy to understand by the average athlete, combining medical research, anecdotal information, personal experiences, and instinctive hypotheses, interspaced with cartoons in extremely poor taste. Running throughout the text was a jaded, pessimistic, and sometimes overtly cruel streak of humor. Although the USH ended up becoming a subculture sensation to hardcore muscleheads, I never made a lot of money on the thing; didn't make the cover of Time or Newsweek either. Athletes who used steroids embraced the schizoid dictum with a collective mutter of, 'Finally, someone said itl' The medical community was predictably miffed, and inadvertently I evolved into a kind of cult crusader, although anti-steroid people like Dr. Bob (Death in the Locker Room) Goldman might consider me the Jim Jones of such a cult. I've been labeled the bad boy of bodybuilding, the renegade researcher; 'steroid guru' is popular lately. The USH never sold well because basically I was a lousy salesman. The book wasn't copyrighted and it was easy to photocopy. It was sold by direct mail order through specialty magazines and most of the magazines pulled the ad out as soon as it was apparent that the book was advocating DRUG USE. This does not mean that the book didn't get around. I must have sold at least 40,000 copies over the years. I've seen tons of photocopies. I own various foreign language editions of the USH. It has been rewritten and passed around in France, Germany, Holland, and Sweden, along with bootleg copies sold mail order in two British bodybuilding magazines. Just last month I saw an ad for it in a newsletter originating in Canada. Over the six years that this crude pamphlet has been circulating around, it has been quoted on CBS's 60 minutes, in Sports Illustrated, the Los Angeles Times, the New York Times, and in just about every major (and minor) bodybuilding magazine. If on one day I wasn't hounded by the BBC, I was followed by the FBI. I don't know just how many federal agencies picked through my trash for over three years, but I know they did. Someone from the FDA told me how frustrated they were that I shredded all the really important trash with the same type of shredder that they used. Copyright © 1989 by Daniel Duchaine Copyright © 2006 by QFAC, Inc. All Rights Reserved. I'm pretty much ambivaient about this continuing notoriety, mostly because I never imagined that the USH was going to be considered all that great or cataclysmic a book about steroids. I still wonder, why is the general public SO interested in these drugs; very few people use them. I was always a little embarassed in calling it a 'book', as short as it was. I'm a college graduate but the only college science courses I took were in Astronomy. I never worked with a medical doctor, nor are there any pharmacists in my family. Actually I never took any medical or biology courses in high school or in college. I did dissect an earthworm in elementary school. In spite of all this (maybe because of it?) I will say with complete confidence that I have turned out to be the most competent expert on practical steroid use. No doctor, researcher, coach, or also-ran guru can match what I (sometimes accidentally) accomplished over the years. Sorry if I sound arrogant, but I have encountered no one having my abilities in counseling athletes (both male and female) on improving their size, strength, appearance and performance without compromising their health. Let me be the first to prick my ballooning ego by saying that I have gotten to this position passively and by default. I do believe that the USH, yes, even the old one, is still the best practical text on steroid use only because all the others are so bad. Oh, they've been written by MDs and PhDs, and were printed more attractively, but as far as a manual that an average athlete can read, understand, and use for immediate, discernible benefit, the ratty, outdated, little USH still has no peer. Let me confess that I don't feel all that swell about being the de facto steroid guru. There certainly are more knowledgable people able to do the work. I guess that my combination of being smart and knowledgable and creative along with the correct temperament (also known as a morbid fascination) for the work has kept me unique in this field so far. The other major reason I have become the harbinger of hormonious truth is simply because I have the least to lose in confronting the self-appointed medical authorities with three unthinkable words: You are wrong. But, as I've implied, I'm not perfect, which is a graceful way of admitting I've not always been right. As I learned more about the idiosyncrasies of steroid use in athletics, I realized that I had made some bloopers in the original USH. Granted, sometimes I knowingly bent the truth a bit to make it easier to understand, but occasionally I was flat out wrong. Not so seriously that the information would endanger someone's health, but details here and there needed to be corrected. Also, new products had hit the black market, the designer steroids, and were being used with no guidance or rationality. So, motivated by a sort of skewed sense of moral obligation, I began to publish sporadic Updates which corrected any boners I had made in the first USH, along with reviewing the new and fashionable steroids that athletes were using. However, I ran into trouble here too; sometimes the Updates contained errors, mostly apparent only to myself and a handful of anabolic adepts as more information accrued. The years rolled by and I realized that I really should update the Updates. However, at this time the media covering athletics in America became rampantly anti-steroid. The megalomaniac of muscle, Ben Weider (who, inarguably, owns the sport of bodybuilding), and his idiot-savant Bob Goldman, pumped up all the Weider specialty magazines (Muscle & Fitness, Flex, Shape, Men's Fitness) with relentless anti-steroid propaganda, spreading it from these specialty periodicals, to newspapers, and on to television. Then Copyright © 1989 by Daniel Duchaine Copyright © 2006 by QFAC, Inc. All Rights Reserved. the federal government jumped into the misinformation spree, abandoned their usual laissez-faire attitude and started cracking down on the relatively benign-but-illegal black market steroid trade. At this point I said to myself, Time to make that mid-life career change, do something really unusual, like pursue what you spent six years in college for.' But then it happened: I got pissed, I stayed pretty calm when I was arrested. I didn't got too upset when they set my bail at one million dollars. I view the two months I spent in jail as a rewarding experience. But I had a very hard time staying nice and complacent when, knowing the subject intimately, I knew I was being lied to. And I'm going to tell you with all intellectual and heartfelt conviction that the government, the Weider Media, Dr.
Load more

Recommended publications
  • Download (PDF 277.63
    PROJECT REVIEW “Characterization of the main metabolites of 17-methylstenblone and 17 methylmethenolone produced by human hepatocytes and liver fractions” Prof C. Ayotte, (INRS-Institut Armand-Frappier, Canada) New steroids openly appear on the market in products labelled with a rather confusing nomenclature. Once characterized, pharmaceutical grade products not being available, knowledge of the biotransformation pathways essential to an efficient detection of utilization by athletes is difficult to gain since administration to human volunteers should be restricted to the minimum. The alternative is a reliable in vitro model. Human hepatocytes, fresh or cryopreserved are now available commercially. We have successfully produced and identified phase I metabolites from incubations of human hepatocytes with different steroids, such as 17-methyldrostanolone and desoxymethyltestosterone (DMT). The aim of this project is to produce in vitro from human hepatocytes and liver fractions the metabolites of two steroids, the 17-methylated derivatives of stenbolone and its isomer methenolone. The principal metabolites will be synthesized and characterized by NMR and mass spectrometry. The characterization of metabolites will enable the identification of markers of utilization to be incorporated in routine testing methods. The approach for the chemical synthesis of metabolites will be shared with NMI insuring the distribution to other doping control laboratories. Improving the knowledge of steroid biotransformation is a further benefit from these studies. Characterization of 17-Methylstenbolone and 17-Methylmethenolone and Identification of Metabolites Produced by Human Hepatocytes and Liver Fractions WADA Project no. 11A16CA Christiane Ayotte, Philippe Räss, Alexandre Sylvestre, INRS-Institut Armand-Frappier Summary We have synthesized and characterized two designer steroids, 17α-methylmethenolone and 17α- methylstenbolone; the latter is proposed on the internet and two groups have reported different and contradictory results.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,642,912 B2 Kisak Et Al
    USOO9642912B2 (12) United States Patent (10) Patent No.: US 9,642,912 B2 Kisak et al. (45) Date of Patent: *May 9, 2017 (54) TOPICAL FORMULATIONS FOR TREATING (58) Field of Classification Search SKIN CONDITIONS CPC ...................................................... A61K 31f S7 (71) Applicant: Crescita Therapeutics Inc., USPC .......................................................... 514/171 Mississauga (CA) See application file for complete search history. (72) Inventors: Edward T. Kisak, San Diego, CA (56) References Cited (US); John M. Newsam, La Jolla, CA (US); Dominic King-Smith, San Diego, U.S. PATENT DOCUMENTS CA (US); Pankaj Karande, Troy, NY (US); Samir Mitragotri, Santa Barbara, 5,602,183 A 2f1997 Martin et al. CA (US); Wade A. Hull, Kaysville, UT 5,648,380 A 7, 1997 Martin 5,874.479 A 2, 1999 Martin (US); Ngoc Truc-ChiVo, Longueuil 6,328,979 B1 12/2001 Yamashita et al. (CA) 7,001,592 B1 2/2006 Traynor et al. 7,795,309 B2 9/2010 Kisak et al. (73) Assignee: Crescita Therapeutics Inc., 8,343,962 B2 1/2013 Kisak et al. Mississauga (CA) 8,513,304 B2 8, 2013 Kisak et al. 8,535,692 B2 9/2013 Pongpeerapat et al. (*) Notice: Subject to any disclaimer, the term of this 9,308,181 B2* 4/2016 Kisak ..................... A61K 47/12 patent is extended or adjusted under 35 2002fOOO6435 A1 1/2002 Samuels et al. 2002fOO64524 A1 5, 2002 Cevc U.S.C. 154(b) by 204 days. 2005, OO 14823 A1 1/2005 Soderlund et al. This patent is Subject to a terminal dis 2005.00754O7 A1 4/2005 Tamarkin et al.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]
  • An Update the Increasing Popularity of Anabolic Androgenic Steroids
    Anabolic Androgenic Steroid Abuse in the United Kingdom; An Update The increasing popularity of anabolic androgenic steroids. Carrie Mullena, Benjamin J Whalleyb, Fabrizio Schifanoc, Julien S Bakerd a School of Computing, Engineering and Physical Sciences, University of the West of Scotland, Paisley, PA1 2BE b School of Chemistry, Food and Nutritional Sciences, and Pharmacy, The University of Reading, Whiteknights, Reading, Berkshire, RG6 6AP c School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Hertfordshire, AL10 9EU d Centre for Health and Exercise Science Research, Department of Sport, Physical Education and Health, Hong Kong Baptist University, Kowloon Tong, Hong Kong. Correspondence Carrie Mullen, School of Computing, Engineering and Physical Sciences, University of the West of Scotland, Paisley, PA1 2BE Tel 0044 141 848 3845 email [email protected] 7,081 Words Abstract Anabolic androgenic steroids (AASs) are prescribed for medical conditions related to low testosterone. Abuse of AASs has surged as they become increasingly recognised as potent image enhancement drugs. The primary goal of most abusers is to obtain what they consider to be a more attractive outward appearance. Abuse is complex. There are a vast range of AAS substances available, although due to their illicit nature, the true composition of AAS substances is difficult to evaluate. Users follow dosing patterns which incorporate a number This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bph.14995 This article is protected by copyright.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    THE ORGANIC CHEMISTRY OF DRUG SYNTHESIS VOLUME 3 DANIEL LEDNICER Analytical Bio-Chemistry Laboratories, Inc. Columbia, Missouri LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS New York • Chlchester • Brisbane * Toronto • Singapore Copyright © 1984 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Section 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging In Publication Data: (Revised for volume 3) Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." Includes bibliographical references and index. 1. Chemistry, Pharmaceutical. 2. Drugs. 3. Chemistry, Organic—Synthesis. I. Mitscher, Lester A., joint author. II. Title. [DNLM 1. Chemistry, Organic. 2. Chemistry, Pharmaceutical. 3. Drugs—Chemical synthesis. QV 744 L473o 1977] RS403.L38 615M9 76-28387 ISBN 0-471-09250-9 (v. 3) Printed in the United States of America 10 907654321 With great pleasure we dedicate this book, too, to our wives, Beryle and Betty. The great tragedy of Science is the slaying of a beautiful hypothesis by an ugly fact. Thomas H. Huxley, "Biogenesis and Abiogenisis" Preface Ihe first volume in this series represented the launching of a trial balloon on the part of the authors. In the first place, wo were not entirely convinced that contemporary medicinal (hemistry could in fact be organized coherently on the basis of organic chemistry.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20060018934A1 (19) United States (12) Patent Application Publication (10) Pub. N0.: US 2006/0018934 A1 Vaya et al. (43) Pub. Date: Jan. 26, 2006 (54) NOVEL DRUG DELIVERY SYSTEM (30) Foreign Application Priority Data (76) Inventors; Navin Vaya, Gujarat (IN); Rajesh Aug. 5, 2002 (IN) ............................... .. 698/MUM/2002 Singh Karan, Gujarat (IN); Suni] Aug. 5, 2002 (IN) .... .. 696/MUM/2003 Sadanand Nadkarni, Gujarat (IN); Jan. 22, 2003 (IN) ................................. .. 81/MUM/2003 Vinod Kumar Gupta, Gujarat (IN) Publication Classi?cation Correspondence Address: HEDMAN & COSTIGAN RC. (51) Int. Cl. 1185 AVENUE OF THE AMERICAS A61K 9/00 (2006.01) NEW YORK, NY 10036 (US) A61K 9/24 (2006.01) (52) US. Cl. .......................................... .. 424/400; 424/472 (57) ABSTRACT (21) Appl. No.: 11/134,632 A novel modi?ed release dosage form comprising of a high (22) Filed: May 19, 2005 solubility active ingredient, Which utilizes dual retard tech nique to effectively reduce the quantity of release controlling Related US. Application Data agents. Present invention can optionally comprise addition ally another active ingredient as an immediate release form (63) Continuation-in-part of application No. 10/630,348, or modi?ed release form. Present invention also relates to a ?led on Jul. 29, 2003. process for preparing the said formulation. Patent Application Publication Jan. 26, 2006 Sheet 1 0f 5 US 2006/0018934 A1 FIGURE 1 (a) FIGURE 1 (b) Patent Application Publication Jan. 26, 2006 Sheet 2 0f 5 US 2006/0018934 A1 FIGURE 2 120 — (95) 100 80 60 ActiveIngredientRelease 4O - 2O - 0 2 4 6 8 10 12 14 16 18 2O 22 24 Q 26 Time (hour) Patent Application Publication Jan.
    [Show full text]
  • Chapter 246-883 WAC PHARMACEUTICAL—SALES REQUIRING PRESCRIPTIONS
    Chapter 246-883 Chapter 246-883 WAC PHARMACEUTICAL—SALES REQUIRING PRESCRIPTIONS WAC Authority: 1979 1st ex. s. c 139. 79-09-138 (Order 149, Resolution No. 246-883-020 Identification of legend drugs for purposes of chapter 9/79), § 360-32-050, filed 9/5/79.] 69.41 RCW. 246-883-025 Introductory trade or stock packages. 246-883-030 Ephedrine prescription restrictions. WAC246-883-025 246-883-025 Introductory trade or stock pack- 246-883-040 Regulated steroids. 246-883-050 Theophylline prescription restrictions. ages. Introductory trade or stock packages may be distributed by registered drug manufacturers to licensed pharmacies 246-883-020 under the following conditions: WAC 246-883-020 Identification of legend drugs for purposes of chapter 69.41 RCW. (1) In accordance with (1) The package shall be invoiced by the drug manufac- chapter 69.41 RCW, the board of pharmacy finds that those turer as a no charge sale. drugs which have been determined by the Food and Drug (2) The product shall be distributed by the manufacturer Administration, under the Federal Food, Drug and Cosmetic to the pharmacy by mail or common carrier. Act, to require a prescription under federal law should also be (3) The drug's package shall not be marked as a sample classified as legend drugs under state law because of their or with any other labeling that is inconsistent with the claim toxicity or potential for harmful effect, the methods of their that the manufacturer intended the package for sale. use and the collateral safeguards necessary to their use, indi- (4) The manufacturer shall be limited to distributing one cate that they are only safe for use under the supervision of a introductory package of each dosage strength of a product on practitioner.
    [Show full text]
  • Sports Drug Testing and Toxicology TOP ARTICLES SUPPLEMENT
    Powered by Sports drug testing and toxicology TOP ARTICLES SUPPLEMENT CONTENTS REVIEW: Applications and challenges in using LC–MS/MS assays for quantitative doping analysis Bioanalysis Vol. 8 Issue 12 REVIEW: Current status and recent advantages in derivatization procedures in human doping control Bioanalysis Vol. 7 Issue 19 REVIEW: Advances in the detection of designer steroids in anti-doping Bioanalysis Vol. 6 Issue 6 Review For reprint orders, please contact [email protected] 8 Review 2016/05/28 Applications and challenges in using LC–MS/MS assays for quantitative doping analysis Bioanalysis LC–MS/MS is useful for qualitative and quantitative analysis of ‘doped’ biological Zhanliang Wang‡,1, samples from athletes. LC–MS/MS-based assays at low-mass resolution allow fast Jianghai Lu*,‡,2, and sensitive screening and quantification of targeted analytes that are based on Yinong Zhang1, Ye Tian2, 2 ,2 preselected diagnostic precursor–product ion pairs. Whereas LC coupled with high- Hong Yuan & Youxuan Xu** 1Food & Drug Anti-doping Laboratory, resolution/high-accuracy MS can be used for identification and quantification, both China Anti-Doping Agency, 1st Anding have advantages and challenges for routine analysis. Here, we review the literature Road, ChaoYang District, Beijing 100029, regarding various quantification methods for measuring prohibited substances in PR China athletes as they pertain to World Anti-Doping Agency regulations. 2National Anti-doping Laboratory, China Anti-Doping Agency, 1st Anding Road, First draft submitted:
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0058896 A1 Dietrich Et Al
    US 200400.58896A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0058896 A1 Dietrich et al. (43) Pub. Date: Mar. 25, 2004 (54) PHARMACEUTICAL PREPARATION (30) Foreign Application Priority Data COMPRISING AN ACTIVE DISPERSED ON A MATRIX Dec. 7, 2000 (EP)........................................ OO126847.3 (76) Inventors: Rango Dietrich, Konstanz (DE); Publication Classification Rudolf Linder, Kontanz (DE); Hartmut Ney, Konstanz (DE) (51) Int. Cl." ...................... A61K 31156; A61K 31/4439 (52) U.S. Cl. ........................... 514/171; 514/179; 514/338 Correspondence Address: (57) ABSTRACT NATH & ASSOCATES PLLC 1030 FIFTEENTH STREET, N.W. The present invention relates to the field of pharmaceutical SIXTH FLOOR technology and describes a novel advantageous preparation WASHINGTON, DC 20005 (US) for an active ingredient. The novel preparation is Suitable for 9 producing a large number of pharmaceutical dosage forms. (21) Appl. No.: 10/433,398 In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix com (22) PCT Filed: Dec. 6, 2001 posed of one or more excipients Selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid (86) PCT No.: PCT/EPO1/14307 eSter. US 2004/0058896 A1 Mar. 25, 2004 PHARMACEUTICAL PREPARATION 0008 Further subject matters are evident from the claims. COMPRISING AN ACTIVE DISPERSED ON A MATRIX 0009. The preparations for the purpose of the invention preferably comprise numerous individual units in which at least one active ingredient particle, preferably a large num TECHNICAL FIELD ber of active ingredient particles, is present in an excipient 0001. The present invention relates to the field of phar matrix composed of the excipients of the invention (also maceutical technology and describes a novel advantageous referred to as active ingredient units hereinafter).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0010208A1 Shashoua Et Al
    US 2002001 0208A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0010208A1 Shashoua et al. (43) Pub. Date: Jan. 24, 2002 (54) DHA-PHARMACEUTICAL AGENT Related U.S. Application Data CONJUGATES OF TAXANES (63) Continuation of application No. 09/135,291, filed on (76) Inventors: Victor Shashoua, Brookline, MA (US); Aug. 17, 1998, now abandoned, which is a continu Charles Swindell, Merion, PA (US); ation of application No. 08/651,312, filed on May 22, Nigel Webb, Bryn Mawr, PA (US); 1996, now Pat. No. 5,795,909. Matthews Bradley, Layton, PA (US) Publication Classification Correspondence Address: Edward R. Gates, Esq. (51) Int. Cl." ............................................ A61K 31/337 Wolf, Greenfield & Sacks, P.C. (52) U.S. Cl. .............................................................. 514/449 600 Atlantic Avenue Boston, MA 02210 (US) (57) ABSTRACT The invention provides conjugates of cis-docosahexaenoic (21) Appl. No.: 09/846,838 acid and pharmaceutical agents useful in treating noncentral nervous System conditions. Methods for Selectively target 22) Filled: Mayy 1, 2001 ingg pharmaceuticalp agents9. to desired tissues are pprovided. Patent Application Publication Jan. 24, 2002 Sheet 1 of 14 US 2002/0010208A1 1 OO 5 O -5OO - 1 OO-9 -8 -7 -6 -5 -4 LOG-10 OF SAMPLE CONCENTRATION (MOLAR) CCRF-CEM-o- SR ----- RPM-8226----- K-562- - -A - - HL-60 (TB) -g- - MOLT4: ... O Fig. 1 1 OO 5 O -5OO -1 O O -8 -7 -6 -5 -4 -- 9 LOGo OF SAMPLE CONCENTRATION (MOLAR) A549/ATCC-o-NS326. NCEKVX 28. --Q-- NCI-H322M-...-a---Eidsf8::... NC-H522--O-- HOP-62---Fig. 2 a-- NC-H460.-------- Patent Application Publication Jan.
    [Show full text]
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
    Molecules 2016, 21, 75; doi:10.3390/molecules21010075 S1 of S110 Supplementary Materials: Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs Fei Mao 1, Wei Ni 1, Xiang Xu 1, Hui Wang 1, Jing Wang 1, Min Ji 1 and Jian Li * Table S1. Common names, indications, CAS Registry Numbers and molecular formulas of 6891 approved drugs. Common Name Indication CAS Number Oral Molecular Formula Abacavir Antiviral 136470-78-5 Y C14H18N6O Abafungin Antifungal 129639-79-8 C21H22N4OS Abamectin Component B1a Anthelminithic 65195-55-3 C48H72O14 Abamectin Component B1b Anthelminithic 65195-56-4 C47H70O14 Abanoquil Adrenergic 90402-40-7 C22H25N3O4 Abaperidone Antipsychotic 183849-43-6 C25H25FN2O5 Abecarnil Anxiolytic 111841-85-1 Y C24H24N2O4 Abiraterone Antineoplastic 154229-19-3 Y C24H31NO Abitesartan Antihypertensive 137882-98-5 C26H31N5O3 Ablukast Bronchodilator 96566-25-5 C28H34O8 Abunidazole Antifungal 91017-58-2 C15H19N3O4 Acadesine Cardiotonic 2627-69-2 Y C9H14N4O5 Acamprosate Alcohol Deterrant 77337-76-9 Y C5H11NO4S Acaprazine Nootropic 55485-20-6 Y C15H21Cl2N3O Acarbose Antidiabetic 56180-94-0 Y C25H43NO18 Acebrochol Steroid 514-50-1 C29H48Br2O2 Acebutolol Antihypertensive 37517-30-9 Y C18H28N2O4 Acecainide Antiarrhythmic 32795-44-1 Y C15H23N3O2 Acecarbromal Sedative 77-66-7 Y C9H15BrN2O3 Aceclidine Cholinergic 827-61-2 C9H15NO2 Aceclofenac Antiinflammatory 89796-99-6 Y C16H13Cl2NO4 Acedapsone Antibiotic 77-46-3 C16H16N2O4S Acediasulfone Sodium Antibiotic 80-03-5 C14H14N2O4S Acedoben Nootropic 556-08-1 C9H9NO3 Acefluranol Steroid
    [Show full text]
  • LPO' Enforcement in 2021
    Voluntary Report – Voluntary - Public Distribution Date: April 30, 2021 Report Number: MX2021-0023 Report Name: Mexico Organic Law 'LPO' Enforcement in 2021 Country: Mexico Post: Mexico City Report Category: Special Certification - Organic/Kosher/Halal Prepared By: USDA Approved By: Daniel Alvarado Report Highlights: On December 26, 2020, Mexico published a measure that requires most organic raw materials and bulk products to be certified to Mexico’s Organic Law (LPO) standards by June 26, 2021. The Measure includes an annex that lists the products which will require proof of LPO certification at the border. While USDA has requested an extension of the June 26, 2021 deadline, Mexico has not approved an extension and U.S. stakeholders should prepare for compliance on June 26, 2021. Mexico’s organics regulator, the National Service for Animal and Plant Health, Food Safety and Quality (SENASICA), is fully responsible for certifying and enforcing the LPO requirements. This report contains a summary of SENASICA’s public statements on this Measure and contact information for parties seeking additional information. THIS REPORT CONTAINS ASSESSMENTS OF COMMODITY AND TRADE ISSUES MADE BY USDA STAFF AND NOT NECESSARILY STATEMENTS OF OFFICIAL U.S. GOVERNMENT POLICY Executive Summary: On December 26, 2020, Mexico published a measure (the Measure) stating products which will be marketed as organic in Mexico will need to show compliance at the border with Mexico’s organic law (LPO). The Measure includes an annex listing the scope of products (by HS code) that must be certified. A summary of this list is included in the pages of this report.
    [Show full text]